Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(03): 148-161
DOI: 10.1055/s-0043-110481
Article
© Georg Thieme Verlag KG Stuttgart · New York

Protective Effect and Potential Mechanism of Simvastatin on Myocardial Injury Induced by Diabetes with Hypoglycemia

Haiqing Li
1   Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
,
Qianqian Zhao
1   Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
,
Rong Liu
1   Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
,
Lan Yang
1   Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
,
Huanzhen Chen
2   Department of Cardiovascular Internal Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
,
Xiangli Cui
1   Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
› Author Affiliations
Further Information

Publication History

received 16 February 2016
revised 02 May 2017

accepted 02 May 2017

Publication Date:
17 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background Simvastatin has been reported to reduce cardiovascular related morbidity and mortality in clinical trials which was independent of its cholesterol-lowering effect. This study aims to investigate the protective effect of simvastatin on myocardial injury caused by diabetic hypoglycemia and the possible underlying mechanism.

Methods We used streptozotocin (STZ) at a dose of 55 mg/kg to induce diabetes mellitus (DM) and over-dose insulin to induce hypoglycemia to establish diabetic hypoglycemia rat models. The cardiac protective effect of simvastatin treatment (at a dose of 40 mg/kg·d) upon diabetic hypoglycemia models was assessed. Ex vivo cardiac function, cardiomyocyte inotropic property and calcium transient were evaluated. The expression levels of microRNA (miRNA) and NF-κB in heart tissues were investigated.

Results Both systolic and diastolic functions in diabetic rats were weakened, and further worsened in diabetic hypoglycemia rats, partially restored after administration of simvastatin. The protective effect of simvastatin on cardiac function under diabetic hypoglycermia was associated with decreased intracellular calcium and increased calcium sensitivity. miRNA array showed a differential profile of miRNA expression existed in diabetic hypoglycemia rats compared with diabetic non-hypoglycemia group, and that simvastatin could reverse the altered miRNA expression in diabetic hypoglycemia group.

Conclusion Simvastatin has protective effect on myocardial injury caused by diabetes with hypoglycemia, which is associated with increased calcium sensitivity, decreased NF-κB expression and altered miRNA expression profile.

Key words

diabetic hypoglycemia - simvastatin - cardiac dysfunction - NF-κB - miRNA
 

  • References

  • 1 Villegas R, Shu XO, Li H. et al. Physical activity and the incidence of type 2 diabetes in the Shanghai women’s health study. Int J Epidemiol 2006; 35: 1553-1562
    CrossrefPubMedGoogle Scholar
  • 2 Monesi L, Baviera M, Marzona I. et al. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med 2012; 29: 385-392
    CrossrefPubMedGoogle Scholar
  • 3 Rayburn WF. Diagnosis and classification of diabetes mellitus: Highlights from the American Diabetes Association. J Reprod Med 1997; 42: 585-586
    PubMedGoogle Scholar
  • 4 Wang W, Peng W, Zhang X. et al. Chromosome 9p21.3 polymorphism in a Chinese Han population is associated with angiographic coronary plaque progression in non-diabetic but not in type 2 diabetic patients. Cardiovascular Diabetology 2010; 9: 33
    CrossrefPubMedGoogle Scholar
  • 5 Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes TechnolTher. 2012; 14 (Suppl. 01) S51-S58
    PubMedGoogle Scholar
  • 6 Fisman EZ, Motro M, Tenenbaum A. et al Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil 2004; 11: 135-143
    CrossrefPubMedGoogle Scholar
  • 7 Zanchetti A, Hansson L, Dahlof B. et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149-1159
    CrossrefPubMedGoogle Scholar
  • 8 Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes care 2003; 26: 1902-1912
    CrossrefPubMedGoogle Scholar
  • 9 Laitinen T, Lyyra-Laitinen T, Huopio H. et al. Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects. Ann Noninvasive Electrocardiol 2008; 13: 97-105
    CrossrefPubMedGoogle Scholar
  • 10 Pedersen TR, Kjekshus J, Berg K. et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004; 5: 81-87
    PubMedGoogle Scholar
  • 11 Crisby M. Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis 2005; 9: E3
    PubMedGoogle Scholar
  • 12 Kumai T, Matsumoto N, Koitabashi Y. et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: Candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 195-201
    CrossrefPubMedGoogle Scholar
  • 13 Care A, Catalucci D, Felicetti F. et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-618
    CrossrefPubMedGoogle Scholar
  • 14 vanRooij E, Sutherland LB, Qi X. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579
    CrossrefPubMedGoogle Scholar
  • 15 Ikeda S, He A, Kong SW. et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009; 29: 2193-2204
    CrossrefPubMedGoogle Scholar
  • 16 Li Q, Song XW, Zou J. et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci 2010; 123: 2444-2452
    CrossrefPubMedGoogle Scholar
  • 17 Yang B, Lin H, Xiao J. et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-491
    CrossrefPubMedGoogle Scholar
  • 18 Tatsuguchi M, Seok HY, Callis TE. et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology 2007; 42: 1137-1141
    CrossrefPubMedGoogle Scholar
  • 19 vanRooij E, Sutherland LB, Thatcher JE. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032
    CrossrefPubMedGoogle Scholar
  • 20 Wang J, Huang W, Xu R. et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150-2160
    CrossrefPubMedGoogle Scholar
  • 21 Sun HX, Zeng DY, Li RT. et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012; 60: 1407-1414
    CrossrefPubMedGoogle Scholar
  • 22 Cerda A, Fajardo CM, Basso RG. et al. Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells. Arq Bras Cardiol 2015; 104: 195-201
    PubMedGoogle Scholar
  • 23 Andreasen AS, Kelly M, Berg RM. et al. Type 2 diabetes is associated with altered NF-kappaB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. PloS One 2011; 6: e23999
    CrossrefPubMedGoogle Scholar
  • 24 Baumann B, Salem HH, Boehm BO. Anti-inflammatory therapy in type 1 diabetes. Curr Diab Rep 2012; 12: 499-509
    CrossrefPubMedGoogle Scholar
  • 25 Muller MM, Kuzmits R, Frass M. et al. Purine metabolism of erythrocytes in myotonic dystrophy. J Neurol 1980; 223: 59-66
    CrossrefPubMedGoogle Scholar
  • 26 Goyal BR, Solanki N, Goyal RK. et al. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol 2009; 54: 502-509
    CrossrefPubMedGoogle Scholar
  • 27 Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394
    CrossrefPubMedGoogle Scholar
  • 28 Teng GG, Wang WH, Dai Y. et al. Let-7b is involved in the inflammation and immune responses associated with Helicobacter pylori infection by targeting Toll-like receptor 4. PloS One 2013; 8: e56709
    CrossrefPubMedGoogle Scholar
  • 29 Cammermeyer J. Hypependymal cysts adjacent to and over circumventricular regions in primates. Acta Anat (Basel) 1973; 84: 353-373
    CrossrefPubMedGoogle Scholar
  • 30 Jickling GC, Ander BP, Zhan X. et al. microRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets. PloS One 2014; 9: e99283
    CrossrefPubMedGoogle Scholar
  • 31 Liao XH, Wang N, Zhao DW. et al. NF-kappaB (p65) negatively regulates myocardin-induced cardiomyocyte hypertrophy through multiple mechanisms. Cell Signal 2014; 26: 2738-2748
    CrossrefPubMedGoogle Scholar
  • 32 Li X, Gao L, Cui Q. et al. Sulindac inhibits tumor cell invasion by suppressing NF-kappaB-mediated transcription of microRNAs. Oncogene 2012; 31: 4979-4986
    CrossrefPubMedGoogle Scholar
  • 33 Zhang W, Shen X, Xie L. et al. MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells. J Inflamm (Lond) 2015; 12: 18
    CrossrefPubMedGoogle Scholar
  • 34 Ramachandran S, Karp PH, Osterhaus SR. et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. Am J Respir Cell Mol Biol 2013; 49: 544-551
    CrossrefPubMedGoogle Scholar
  • 35 Chen LJ, Chuang L, Huang YH. et al. MicroRNA mediation of endothelial inflammatory response to smooth muscle cells and its inhibition by atheroprotective shear stress. Circ Res 2015; 116: 1157-1169
    CrossrefPubMedGoogle Scholar
  • 36 Paty BW. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes. Can J Diabetes 2015; 39 (Suppl. 05) S155-S159
    CrossrefPubMedGoogle Scholar
  • 37 Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 2004; 109: II18-II26
    CrossrefPubMedGoogle Scholar
  • 38 Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987
    CrossrefPubMedGoogle Scholar
  • 39 Balke CW, Goldman L. Excitation contraction coupling in cardiac muscle: is there a purely voltage-dependent component?. J Gen Physiol 2003; 121: 349-352
    CrossrefPubMedGoogle Scholar
  • 40 Griffiths H, MacLeod KT. The voltage-sensitive release mechanism of excitation contraction coupling in rabbit cardiac muscle is explained by calcium-induced calcium release. J Gen Physiol 2003; 121: 353-373
    CrossrefPubMedGoogle Scholar
  • 41 Yuan W, Tang C, Zhu W. et al. CDK6 mediates the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy. Mol Cell Biochem 2016; 412: 289-296
    CrossrefPubMedGoogle Scholar
  • 42 Nielsen LB, Wang C, Sorensen K. et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012; 2012: 896362
    PubMedGoogle Scholar
  • 43 Karolina DS, Tavintharan S, Armugam A. et al. Circulating miRNA profiles in patients with metabolic syndrome. The Journal of Clinical Endocrinology and Metabolism 2012; 97: E2271-R2276
    CrossrefPubMedGoogle Scholar
  • 44 Choi DC, Chae YJ, Kabaria S. et al. MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA. J Neurosci 2014; 34: 12725-12737
    CrossrefPubMedGoogle Scholar
  • 45 Rupp H, Maisch B. Control of apoptosis of cardiovascular fibroblasts: A novel drug target. Herz 1999; 24: 225-231
    CrossrefPubMedGoogle Scholar
  • 46 Wright G, Singh IS, Hasday JD. et al. Endotoxin stress-response in cardiomyocytes: NF-kappaB activation and tumor necrosis factor-alpha expression. American Journal of Physiology Heart and Circulatory Physiology 2002; 282: H872-H879
    CrossrefPubMedGoogle Scholar
  • 47 Meiners S, Hocher B, Weller A. et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 2004; 44: 471-477
    CrossrefPubMedGoogle Scholar